PSMA PET Imaging of Recurrent Prostate Cancer
The purpose of this study is to see if a new diagnostic research agent named 68Ga-HBED-CC-PSMA can show prostate cancer on a PET/CT scan that cannot be seen on other standard imaging even when the PSA levels are very low.
Prostate Adenocarcinoma|Prostate Cancer
DRUG: Ga-HBED-iPSMA PET|DIAGNOSTIC_TEST: PET/CT|DIAGNOSTIC_TEST: MRI
Disease localization by PSMA PET/MR, 2 years
PSA relapse free survival in patients undergoing PSMA PET/MR guided SRT, 2 years|Incidence of Treatment-Emergent Adverse Events assessed by common terminology criteria for adverse events (CTCAE v4.0), The safety and tolerability of 68Ga-HBED-iPSMA will be followed by assessing the incidence, nature and severity of toxicities by common terminology criteria for adverse events (CTCAE v4.0), 2 years
The purpose of this study is to see if a new diagnostic research agent named 68Ga-HBED-CC-PSMA can show prostate cancer on a PET/CT scan that cannot be seen on other standard imaging even when the PSA levels are very low.